Fluidx Medical’s GPX Embolic Device Shows Potential for Interventional Oncology Drug Delivery

November 2, 2021—Fluidx Medical Technology announced the presentation of data supporting the potential for oncology drug delivery with the company’s next-generation, doxorubicin-loaded GPX embolic device. The study of the device was presented at the Symposium on Clinical Interventional Oncology (CIO) Conference held October 22-24 in Miami Beach, Florida.

According to Fluidx, the results presented at CIO included an in vitro characterization of the loading and drug release profile of the GPX embolic material loaded with doxorubicin (GPX-DOX). GPX-DOX provided a zero-order release profile for 5 weeks and sustained release out to 100 days. The long linear-release profile is desirable in drug delivery because a constant amount of drug is delivered regardless of the concentration within the carrier.

“GPX is easy to prepare, deliver, and control,” commented Ryan O’Hara, MD, in the company’s press release. Dr. O’Hara, who is an interventional oncologist at the University of Utah in Salt Lake City, continued, “The initial results of GPX as a drug-loadable oncology solution are very promising. GPX would be the first loadable liquid embolic designed for tumor applications.”

The GPX embolic device is designed for simple preparation and quick material delivery. The GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide precipitation. GPX is designed to occlude blood vessels independent of a patient’s coagulation situation, stated Fluidx.

Fluidx Medical Technology, which is based in Salt Lake City, Utah, advised that the GPX embolic device is under development and does not have marketing clearance or approval in any market at this time and is available for investigational use only in New Zealand.